Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Automated Oxygen Titration With the EMILY.AI Device During the Six-Minute Walk Test

16 de novembro de 2026 atualizado por: Aether Tech S.L.

Functional, Clinical, and Predictive Validation Study of the EMILY AI Device in Patients With Acute and Chronic Respiratory Failure: Exercise Substudy (Six-Minute Walk Test) in Ambulatory Patients

This study evaluates EMILY.AI, an investigational (non-CE-marked) smart oxygen valve that automatically adjusts the oxygen flow delivered to a patient.

Adults with chronic respiratory disease who need oxygen during exertion perform two six-minute walk tests on the same day, 30 minutes apart: one with oxygen adjusted automatically by EMILY.AI and one with a fixed oxygen flow delivered through the same device. The order is randomized and participants do not know which test uses automatic titration.

The study compares the time spent within the target saturation range, desaturation, oxygen use, walking distance, breathlessness and participant preference between the two tests. This substudy is part of clinical investigation FJD-EMILY-23-02, whose other substudies are registered in separate records.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

Background Patients with chronic respiratory disease often desaturate during exertion, and fixed-flow oxygen cannot follow the rapid changes in oxygen demand during walking and recovery. EMILY.AI combines a medical-grade oxygen valve with a rule-based algorithm that sets the oxygen flow.

Design Pilot, pragmatic, single-blind, randomized crossover study at Hospital Universitario Fundación Jiménez Díaz (Madrid, Spain). Each participant performs two supervised six-minute walk tests (6MWT) according to the American Thoracic Society guideline, separated by 30 minutes of rest: one with automatic titration by EMILY.AI and one with a fixed flow set by the physician, delivered through the same device so that the participant cannot tell them apart. The order of the two tests is randomized. Each test includes 6 minutes of walking and 2 minutes of standardized recovery.

Safety The medical team knows the device configuration and supervises the valve throughout each test.

Measurements SpO2, heart rate and respiratory rate are recorded with medical-grade pulse oximeters (Nonin, Masimo or Nihon Kohden models), together with distance walked, Borg dyspnoea score, oxygen delivered and participant-reported comfort, breathlessness and preference.

The protocol FJD-EMILY-23-02 also includes a substudy in the Respiratory Intermediate Care Unit and a substudy in a conventional hospital ward, registered separately.

Tipo de estudo

Intervencional

Inscrição (Estimado)

24

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Alba Naya Prieto, MD
  • Número de telefone: +34 915 50 48 00
  • E-mail: alba.naya@fjd.es

Estude backup de contato

  • Nome: Sarah Beatrice Heili Frades, MD, PhD
  • Número de telefone: +34 915 50 48 00
  • E-mail: SHeili@fjd.es

Locais de estudo

      • Madrid, Espanha, 28040
        • Recrutamento
        • Hospital Universitario Fundación Jiménez Díaz
        • Contato:
          • Sarah Beatrice Heili Frades Zimmermann MD, PhD
          • Número de telefone: +34 915 50 48 00
          • E-mail: SHeili@fjd.es
        • Contato:
          • Alba Naya Prieto, MD
          • Número de telefone: +34 915 50 48 00
          • E-mail: alba.naya@fjd.es
        • Investigador principal:
          • Sarah Beatrice Heili Frades Zimmermann, MD, PhD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

40 anos a 90 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Aged 40 to 90 years with a chronic respiratory disease.
  • Indication for exertional oxygen therapy, defined as SpO2 below 88% during a six-minute walk test and/or resting respiratory failure (PaO2 below 60 mmHg).
  • Able to understand the study and sign informed consent.

Exclusion Criteria:

  • Decompensated acute or chronic disease with severe organ involvement, such as cardiovascular disease.
  • Musculoskeletal or neurological disease preventing stable and safe walking.
  • Comorbidities or treatments that, by intensity or dose, limit performance of the tests or interpretation of the results (such as alcohol use, beta-blockers, or other neurological or psychiatric drugs).
  • Walking limitation preventing the six-minute walk test, or cardiovascular or connective tissue disease limiting accurate transcutaneous pulse oximetry.
  • Pregnancy or breastfeeding (women of childbearing potential require a negative pregnancy test at screening).

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: EMILY.AI first, then fixed flow

First 6MWT with automatic titration by EMILY.AI; after 30 minutes of rest, second 6MWT with fixed-flow oxygen through the same device.

Standard care: constant oxygen flow set by the physician, delivered through the EMILY.AI device in fixed mode so that the participant cannot distinguish it from automatic titration.

Investigational smart oxygen valve with rule-based algorithm that adjusts oxygen flow every second from pulse-oximetry SpO2, heart rate and respiratory rate during walking and recovery.

Outros nomes:
  • EMILY.AI Smart Valve
Experimental: Fixed flow first, then EMILY.AI

First 6MWT with fixed-flow oxygen through the device; after 30 minutes of rest, second 6MWT with automatic titration by EMILY.AI.

Standard care: constant oxygen flow set by the physician, delivered through the EMILY.AI device in fixed mode so that the participant cannot distinguish it from automatic titration.

Investigational smart oxygen valve with rule-based algorithm that adjusts oxygen flow every second from pulse-oximetry SpO2, heart rate and respiratory rate during walking and recovery.

Outros nomes:
  • EMILY.AI Smart Valve

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percentage of time with SpO2 within the target range
Prazo: Day 1

Percentage of test time (6 minutes of walking plus 2 minutes of recovery) with SpO2, measured by pulse oximetry, within the predefined target range (88-92%), without delivering oxygen while SpO2 is above the range. Compared between the test with automatic titration by EMILY.AI and the test with fixed flow.

Day 1

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Percentage of test time with SpO2 below 88%
Prazo: Day 1

Percentage of test time (walking and recovery) with SpO2 below 88%, compared between conditions.

Day 1
Number of desaturation episodes with SpO2 below 88%
Prazo: Day 1

Number of episodes per test in which SpO2 falls below 88%, compared between conditions.

Day 1
Time to start of oxygen flow correction
Prazo: Day 1

Time in seconds from SpO2 leaving the target range (88-96%) to the start of an oxygen flow change, compared between conditions.

Day 1
Time to return of SpO2 to the target range
Prazo: Day 1

Time in seconds from SpO2 leaving the target range (88-96%) to its return to the range, compared between conditions.

Day 1
Percentage of test time with oxygen delivered while SpO2 is above 92%
Prazo: Day 1

Percentage of test time (walking and recovery) during which oxygen is delivered while SpO2 is above 92%, compared between conditions.

Day 1
Number of episodes with oxygen delivered while SpO2 is above 92%
Prazo: Day 1

Number of episodes per test in which oxygen is delivered while SpO2 is above 92%, compared between conditions.

Day 1
Total oxygen delivered
Prazo: Day 1

Total volume of oxygen delivered (litres) during each test including recovery, compared between conditions.

Day 1
Mean oxygen flow
Prazo: Day 1

Mean oxygen flow (litres per minute) delivered during each test including recovery, compared between conditions.

Day 1
Six-minute walk distance
Prazo: Day 1

Distance walked (metres), compared between conditions.

Day 1
Change in dyspnoea measured with the modified Borg Dyspnoea Scale
Prazo: Day 1: before and immediately after each six-minute walk test

Change from the start to the end of each test in dyspnoea measured with the modified Borg Dyspnoea Scale, which ranges from 0 (no breathlessness at all) to 10 (maximal breathlessness). Higher scores mean a worse outcome. Compared between conditions.

Day 1: before and immediately after each six-minute walk test
Maximum heart rate
Prazo: Day 1

Maximum heart rate (beats per minute) during each test, compared between conditions.

Day 1
Maximum respiratory rate
Prazo: Day 1

Maximum respiratory rate (breaths per minute) during each test, compared between conditions.

Day 1
Perceived difference in exercise capacity between the two tests
Prazo: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Did you notice differences in your exercise capacity in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Perceived difference in breathlessness between the two tests
Prazo: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Did you notice differences in shortness of breath in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Perceived difference in comfort of oxygen delivery between the two tests
Prazo: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Did you notice differences in the comfort of oxygen delivery in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Preference between the two oxygen delivery systems
Prazo: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Do you prefer either of the two oxygen systems used in the tests?", and, if so, which one. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Preference for continuous automatic flow regulation at home
Prazo: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Would you prefer your home oxygen system to regulate the oxygen flow continuously?". Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Preference for telemonitored home oxygen
Prazo: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Would you prefer your home oxygen system to be telemonitored by the medical team?". Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Sarah Beatrice Heili Frades, MD, PhD, MD, PhD, Hospital Universitario Fundación Jiménez Díaz

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

15 de abril de 2026

Conclusão Primária (Estimado)

20 de dezembro de 2026

Conclusão do estudo (Estimado)

20 de dezembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

28 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

11 de novembro de 2026

Primeira postagem (Real)

16 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • FJD-EMILY-23-02-TM6M
  • FJD-EMILY-23-02 (Outro identificador: Aether Tech SL)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .